Dermal fillers occupy one of the most consistently problematic regulatory borderline positions in global medical product regulation, and Thailand is no exception. Depending on composition, mechanism of action, and intended use, a dermal filler may be classified as a medical device, a cosmetic, a drug, or a combination product that falls across existing regulatory categories. The consequences of misclassification are severe and difficult to reverse: a product placed on the market under the wrong classification faces mandatory withdrawal, potential criminal liability, and the loss of all timeline investment in any distribution relationship built before the problem is identified.
The Classification Framework in Thailand
The TFDA applies a classification framework built around three primary factors: the principal mechanism of action, the site of application, and the primary intended purpose. This framework follows the approach used in the EU and other major markets, but Thai classification rules have their own specific criteria and interpretation practices that do not always produce the same outcome as EU MDR or US FDA classification for the same product. A product classified as a Class II device under EU MDR may be Class 3 or Class 4 in Thailand, and vice versa. Never assume that a classification obtained in another jurisdiction applies in Thailand without a formal Thai-specific classification analysis.
How Hyaluronic Acid Fillers Are Classified
Hyaluronic acid-based fillers that act primarily through physical bulk, filling soft tissue defects without pharmacological, immunological, or metabolic action, are generally classified as medical devices in Thailand, specifically as Class 3 or Class 4 devices. Class 3 and Class 4 medical devices require full registration with a complete technical dossier, clinical evidence (either clinical data or scientific literature justification), and post-market surveillance commitments. This is a substantially higher registration burden than the cosmetic notification pathway, which has relatively low barriers to entry. The temptation to register as a cosmetic to avoid the medical device pathway is the most common and most damaging classification error in this category.
When Fillers Become Drugs or Combination Products
Fillers incorporating pharmacologically active substances — lidocaine for anaesthesia, botulinum toxin, growth factors, or other active pharmaceutical ingredients — may be classified as drugs or combination products in Thailand rather than as medical devices. The classification outcome depends on whether the drug component has a primary, ancillary, or incidental role in the product's intended action. Products where the pharmacological component provides the primary therapeutic effect are likely to trigger the drug registration pathway, which requires a different licensing structure, different technical dossier content, and different post-market obligations than the medical device pathway. Combination products that are genuinely borderline between the two categories may require a formal TFDA classification determination before registration can proceed.
The Cosmetic Misclassification Problem
Cosmetics in Thailand are regulated under a notification system with low barriers and short timelines. Medical devices under Class 3 or 4 require full registration, technical dossier, clinical evidence, and post-market surveillance. The gap between these two pathways in terms of cost, time, and ongoing compliance obligations is substantial. The consequence of importing and distributing a filler as a cosmetic when its intended use, marketing claims, or clinical application bring it within the medical device definition is an enforcement action that can include import holds, mandatory product withdrawal from all distribution channels, fines, and potential criminal liability for operating without the appropriate license. These consequences fall on the Thai importer as the license holder, but they also damage the foreign manufacturer's market position and relationship with the importer.
What to Do Before Importing
Any filler or injectable aesthetic product entering the Thai market should undergo formal classification analysis before importation begins. If the classification is genuinely borderline, a formal classification opinion from the TFDA is available and advisable before investing in registration or distribution. DeeMED Consulting provides borderline product classification analysis and registration strategy for aesthetic injectables and combination products in the Thai market, including TFDA classification opinion applications where appropriate.